Session Title: Cornea
Session Date/Time: Sunday 17/02/2013 | 08:30-11:00
Paper Time: 09:29
Venue: Hall 2
First Author: : S.Anisimov RUSSIA
Co Author(s): :
Purpose:
To develop a new method of personalized local cross-linking, implement this type of surgery in the clinical practice, to assess the clinical results in patients with primary and secondary corneal ectasies.
Setting:
“East-Sight” Eye Center, Moscow, Russia.
Methods:
Clinical outcomes in 38 eyes of 19 patients treatment were evaluated. There were 12 patients with keratoconus, 7 patients had corneal ectasies after LASIK operations.
To evaluate corneal ectasies we used routine methods of examination (refractometry, keratopachimetry, biomicroscopy) we also analyzed corneal hysteresis (ocular response analyzer (ORA) (Reichert, USA) and corneal topogramms (Orbscan Bausch&Lomb, USA).
We used a personalized cross-linking device for phototherapy EVOLUTION (“Transcontact”, Russia) and 1% Riboflavin (“Farmstandart-Ufavita”, Russia). Individual masks were printed on the cutting plotter (“GraftRobo”, Japan).
We converted corneal topogramms into the tenzotopogramms using the “Evolution” mathematical program. Zones of reduced strength were marked and transferred using a laser printer on the diaphragm mask. The cross-linking procedure was performed by so-called “Zurich protocols “ through the individual mask.
Results:
Follow-up period was 18 months for all patients. In all cases we observed stabilization of refraction. We found a marked reduction in visual acuity (1-3 lines) 3 months after the procedure. This process was associated with the appearance of lung opacification in the area of exposure of the UV. In 4-6 months after the procedure, 67% of operated patients noted improvement in visual acuity (they added 1-4 lines), due to the reduction of corneal astigmatism.
Conclusions:
Method of the personalized cross-linking is less invasive in comparison with the classic method. After the operation we received stabilization of the refraction and improvement in best corrected visual acuity.
Financial Disclosure:
None